X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (194) 194
Publication (23) 23
Book / eBook (10) 10
Book Review (3) 3
Conference Proceeding (3) 3
Book Chapter (2) 2
Patent (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (89) 89
male (67) 67
middle aged (63) 63
female (59) 59
aged (48) 48
index medicus (43) 43
adult (37) 37
multiple myeloma (33) 33
hematology (32) 32
oncology (28) 28
transplantation (19) 19
aged, 80 and over (18) 18
medicine & public health (17) 17
multiple myeloma - drug therapy (16) 16
cancer (15) 15
bortezomib (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
chemotherapy (13) 13
surgery (13) 13
dexamethasone (11) 11
treatment outcome (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
prognosis (10) 10
risk factors (10) 10
liver transplantation (9) 9
multiple myeloma - mortality (9) 9
prospective studies (9) 9
retrospective studies (9) 9
thalidomide - administration & dosage (9) 9
analysis (8) 8
care and treatment (8) 8
disease-free survival (8) 8
drug therapy (8) 8
italy (8) 8
multiple myeloma - diagnostic imaging (8) 8
patients (8) 8
therapy (8) 8
follow-up studies (7) 7
health aspects (7) 7
management (7) 7
multiple myeloma - therapy (7) 7
radiology, nuclear medicine & medical imaging (7) 7
radiopharmaceuticals (7) 7
survival (7) 7
technetium tc 99m sestamibi (7) 7
combined modality therapy (6) 6
diagnosis (6) 6
gastroenterology & hepatology (6) 6
medicine, general & internal (6) 6
multiple myeloma - diagnosis (6) 6
multiple myeloma - pathology (6) 6
prednisone (6) 6
radionuclide imaging (6) 6
research (6) 6
salvage therapy (6) 6
survival analysis (6) 6
thalidomide (6) 6
thalidomide - adverse effects (6) 6
antineoplastic agents - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
bendamustine (5) 5
bone marrow (5) 5
case-control studies (5) 5
combination (5) 5
disease (5) 5
disease progression (5) 5
fluorouracil - administration & dosage (5) 5
health care sciences & services (5) 5
immunology (5) 5
italy - epidemiology (5) 5
lenalidomide (5) 5
liver (5) 5
medical research (5) 5
medicine (5) 5
melphalan - administration & dosage (5) 5
multiple myeloma - complications (5) 5
neoplasm staging (5) 5
nursing (5) 5
pain medicine (5) 5
polymorphism, genetic (5) 5
rehabilitation medicine (5) 5
stem cells (5) 5
tomography, x-ray computed (5) 5
aged patients (4) 4
animals (4) 4
antineoplastic agents - adverse effects (4) 4
bone-marrow (4) 4
boronic acids - administration & dosage (4) 4
boronic acids - adverse effects (4) 4
cardiac & cardiovascular systems (4) 4
case report (4) 4
dexamethasone - administration & dosage (4) 4
diagnosis, differential (4) 4
diagnostic radiology (4) 4
drug administration schedule (4) 4
echocardiography (4) 4
efficacy (4) 4
expression (4) 4
fluorodeoxyglucose f18 (4) 4
genotype (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2004, Storia e arte in Terra d'Otranto / Università degli studi di Lecce, Dipartimento dei beni delle arti e della storia, ISBN 9788880865339, Volume 1, 155
Book
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1617 - 1629
Summary Background High-dose melphalan plus autologous stem-cell transplantation (ASCT) is the standard approach in transplant-eligible patients with newly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | ONCOLOGY | CONSOLIDATION THERAPY | INITIAL TREATMENT | THALIDOMIDE | BORTEZOMIB | INDUCTION | STEM-CELL TRANSPLANTATION | DEXAMETHASONE COMBINATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Melphalan - therapeutic use | Hematopoietic Stem Cell Transplantation - mortality | Cyclophosphamide - therapeutic use | Thalidomide - analogs & derivatives | Multiple Myeloma - therapy | Time Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Maintenance Chemotherapy | Chemotherapy, Adjuvant | Thalidomide - adverse effects | Prednisone - adverse effects | Multiple Myeloma - diagnosis | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease Progression | Disease-Free Survival | Czech Republic | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Thalidomide - therapeutic use | Australia | Prednisone - therapeutic use | Medical colleges | Cyclophosphamide | Care and treatment | Chemotherapy | Dexamethasone | Multiple myeloma | Stem cells | Product development | Prednisone | Transplantation | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 895 - 905
In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than... 
MEDICINE, GENERAL & INTERNAL | PREDNISONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | LENALIDOMIDE | INITIAL TREATMENT | RANDOMIZED CONTROLLED-TRIAL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5905 - 5905
Abstract Aims: The objective of this study was to compare the efficacy and safety of pegfilgrastim in patients affected by heavily pretreated MM, treated with... 
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2007, Volume 25, Issue 10, pp. 1247 - 1254
Journal Article
Journal Article
Gastric Cancer, ISSN 1436-3291, 7/2013, Volume 16, Issue 3, pp. 411 - 419
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 9/2018, Volume 26, Issue 9, pp. 3111 - 3116
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e18313 - e18313
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 3/2017, Volume 25, Issue 3, pp. 839 - 845
Journal Article
European Journal of Haematology, ISSN 0902-4441, 05/2016, Volume 96, Issue 5, pp. 544 - 544
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2008, Volume 26, Issue 9, pp. 1427 - 1434
Purpose Regulation of epidermal growth factor receptor (EGFR) signaling pathways may play a relevant role in determining the activity of cetuximab therapy in... 
DEPENDENT CELLULAR CYTOTOXICITY | LUNG-CANCER | CELLS | FUNCTIONAL POLYMORPHISM | FACTOR RECEPTOR EGFR | ONCOLOGY | EPIDERMAL-GROWTH-FACTOR | DINUCLEOTIDE REPEAT POLYMORPHISM | INTRON-1 POLYMORPHISM | MODULATION | GENE-TRANSCRIPTION | Haplotypes | Leucovorin - administration & dosage | Receptor, Epidermal Growth Factor - genetics | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Cetuximab | Gene Expression Regulation, Neoplastic - genetics | Camptothecin - analogs & derivatives | Drug Administration Schedule | Proportional Hazards Models | Signal Transduction - genetics | Genetic Markers | Disease Progression | Polymorphism, Genetic | Disease-Free Survival | Analysis of Variance | Signal Transduction - drug effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Biomarkers, Tumor - genetics | Infusions, Intravenous | Colorectal Neoplasms - pathology | Salvage Therapy - methods | Index Medicus
Journal Article